1 Internal Medicine, Herlev, Herlev and Gentofte Hospital, The Capital Region of Denmark2 Department of Thoracic Medicine and Infectious Disease, Nordsjællands Hospital, The Capital Region of Denmark
Tumour necrosis factor antagonists (anti-TNFα) have become an invaluable treatment against chronic inflammatory diseases. Individuals treated with anti-TNFα have more than a fourfold increased risk of tuberculosis (TB) reactivation depending on the clinical setting and the TNF-antagonist used. All candidates for anti-TNFα treatment in Denmark should be evaluated for possible latent TB using history of exposure, chest X-ray and an interferon-γ release assay. Preventive chemotherapy is recommended for all individuals with latent TB infection before initiation of anti-TNFα as it is expected to reduce the risk of progression to active TB.
Ugeskrift for Laeger, 2011, Vol 173, Issue 12, p. 893-6